Hepatitis C News and Research

Latest Hepatitis C News and Research

Peru: Liver cancer affects young people and children who do not have related risk factors

Liver cancer is the sixth most common cancer worldwide and the third most deadly. It mainly affects men over the age of 40, most often with cirrhosis or hepatitis B or C. But in Peru, it also uncharacteristically affects young people, even children, who do not have the identified related risk factors.

5 Sep 2013

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

The hepatitis C virus hijacks the body's immune system, leaving T cells unable to function. A new study in animal models suggests that blocking a protein that helps the virus thrive could restore immune function, allowing the body to fight infection. The work, led by teams at The Research Institute at Nationwide Children's Hospital and Emory University, was published online Aug. 26 in the Proceedings of the National Academy of Sciences.

4 Sep 2013

Taiwan's HBV immunization program for newborns lowers chronic HBV carriers, incidence of HCC

"Hepatitis B virus infection causes infant fulminant hepatitis, and chronic HBV infection may progress to chronic liver disease and hepatocellular carcinoma. Taiwan launched a nationwide HBV immunization program for newborns in July 1984, which has successfully lowered the prevalence of chronic HBV carriers, incidence of HCC, and mortality of IFH in vaccinated birth cohorts. The mortality of CLD before and after HBV immunization has never been examined," write Chun-Ju Chiang, Ph.D., of National Taiwan University, Taipei, and colleagues.

4 Sep 2013

Research findings could lead to new therapeutic approaches for liver cancer

Liver cancer (Hepatocellular Carcinoma, HCC) usually arises as the result of a chronic, inflammatory liver disease. The most common causes here are excessive alcohol consumption as well as a high-fat diet and also chronic infection with the hepatitis viruses B and C. In the course of the inflammatory process, the liver cells (hepatocytes) die more frequently due to programmed cell death.

30 Aug 2013

Opioid dependence causes greatest health burden of all illicit drugs

The first ever analysis of the global and regional prevalence of dependence upon the four major categories of illicit drugs – amphetamine, cannabis, cocaine, and opioids (such as heroin) – has revealed that opioid dependence causes the greatest health burden (overall death and illness) of all the illicit drugs. The results come from new analysis of the Global Burden of Disease Study 2010, and are published in The Lancet.

29 Aug 2013

HCV treatment with sofosbuvir and ribavirin results in sustained virologic response

Treatment of chronic hepatitis C virus genotype 1 infection with the interferon-free regimen of sofosbuvir and ribavirin resulted in a high sustained virologic response rate in a patient population with unfavorable treatment characteristics, according to a study in the August 28 issue of JAMA.

28 Aug 2013

Research finding could lead to potential treatment for lymphedema

The molecule interleukin-7 is an important immune messenger protein which ensures that a sufficient number of T cells are present in our body for immune defence. Researchers from ETH Zurich have now demonstrated that IL-7 has another important function: it enhances the drainage function of lymphatic vessels, which collect fluid that has leaked out of blood vessels into the body tissue and return it to the bloodstream.

27 Aug 2013

Tel-Aviv Stock Exchange approves new listing of OPKO's common stock

OPKO Health, Inc. (NYSE: OPK), a multi-national biopharmaceutical and diagnostics company, today announced that the Tel-Aviv Stock Exchange ("TASE") has approved the new listing of OPKO's common stock on the TASE beginning on August 21, 2013, under the ticker symbol OPK. OPKO's common stock will thereafter be listed on both the NYSE in the United States and the TASE in Israel.

19 Aug 2013

Powerful mechanism helps viruses evade body's immune response

Researchers at the Salk Institute for Biological Studies have discovered a powerful mechanism by which viruses such as influenza, West Nile and Dengue evade the body's immune response and infect humans with these potentially deadly diseases. The findings may provide scientists with an attractive target for novel antiviral therapies.

19 Aug 2013

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Boehringer Ingelheim today announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete.

15 Aug 2013

Scientists provide insight into emergence of inter-species transmittable viruses

Outbreaks such as the severe acute respiratory syndrome (SARS) Middle East respiratory syndrome coronavirus (MERS) have afflicted people around the world, yet many people think these trends are on the decline.

13 Aug 2013

FDA: New drug Tivicay approved to treat HIV-1 infection

The U.S. Food and Drug Administration today approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply.

13 Aug 2013

Expansion of heroin, opioid medical treatment needed to reduce overdose deaths

A new report from Simon Fraser University researcher Bohdan Nosyk calls for the expansion of heroin and opioid medical treatment to stem the increase of overdose deaths.

7 Aug 2013

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

NanoViricides, Inc. said it has signed a non-disclosure agreement with the Lovelace Respiratory Research Institute. The Company intends to enter into a Master Services Agreement with LRRI for the IND-enabling efficacy studies of both its broad-spectrum injectable and oral FluCide drug candidates.

5 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

New findings may lead to first new animal model for hepatitis C virus

By differentiating monkey stem cells into liver cells and inducing successful infection, researchers from the Icahn School of Medicine at Mount Sinai have shown for the first time that the hepatitis C virus can replicate in monkeys, according to research published in the journal Gastroenterology.

3 Aug 2013

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.

31 Jul 2013

Study: About 50% of fibromyalgia patients have nerve damage

About half of a small group of patients with fibromyalgia - a common syndrome that causes chronic pain and other symptoms - was found to have damage to nerve fibers in their skin and other evidence of a disease called small-fiber polyneuropathy (SFPN). Unlike fibromyalgia, which has had no known causes and few effective treatments, SFPN has a clear pathology and is known to be caused by specific medical conditions, some of which can be treated and sometimes cured.

31 Jul 2013

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Genotype 1 is, worldwide, the most prevalent genotype of the hepatitis C virus. It accounts for around seventy percent of all hepatitis C infections.

30 Jul 2013

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Call it therapeutic poop, if you will, but the best hope yet for an effective treatment of childhood infections with the drug-resistant bacterium C. difficile may come straight from the gut, according to recent research.

30 Jul 2013

Hepatitis C News and Research

Latest Hepatitis C News and Research

Peru: Liver cancer affects young people and children who do not have related risk factors

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

Taiwan's HBV immunization program for newborns lowers chronic HBV carriers, incidence of HCC

Research findings could lead to new therapeutic approaches for liver cancer

Opioid dependence causes greatest health burden of all illicit drugs

HCV treatment with sofosbuvir and ribavirin results in sustained virologic response

Research finding could lead to potential treatment for lymphedema

Tel-Aviv Stock Exchange approves new listing of OPKO's common stock

Powerful mechanism helps viruses evade body's immune response

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Scientists provide insight into emergence of inter-species transmittable viruses

FDA: New drug Tivicay approved to treat HIV-1 infection

Expansion of heroin, opioid medical treatment needed to reduce overdose deaths

NanoViricides, LRRI sign NDA for IND-enabling efficacy studies on FluCide drug candidates

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

New findings may lead to first new animal model for hepatitis C virus

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Study: About 50% of fibromyalgia patients have nerve damage

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in